Skip to content

Building the future of targeted immune therapeutics

Our Approach
Our Team

Building the future of targeted immune therapeutics

Transforming the lives of patients with immune disease through discovery and development of targeted biotherapeutics that rebalance the immune system


Q32 Bio is comprised of an experienced and high-performing team of industry professionals including talented scientists, immunologists, and drug developers empowered to deliver on OUR mission.

Currently, Q32 Bio is advancing a Phase 2 program in alopecia areata:

Our Pipeline
Bempikibart (ADX-914)
Adaptive System Modulator

Bempikibart, Q32 Bio’s most advanced product candidate, is a fully human anti–interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody (mAb) that is designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling. Bempikibart is currently being evaluated in patients with alopecia areata (AA).